1
|
Newman JP, Zhang J, Cuevas-López A, Miller NJ, Honda T, van der Goes MSH, Leighton AH, Carvalho F, Lopes G, Lakunina A, Siegle JH, Harnett MT, Wilson MA, Voigts J. A unified open-source platform for multimodal neural recording and perturbation during naturalistic behavior. bioRxiv 2023:2023.08.30.554672. [PMID: 37693443 PMCID: PMC10491150 DOI: 10.1101/2023.08.30.554672] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/12/2023]
Abstract
Behavioral neuroscience faces two conflicting demands: long-duration recordings from large neural populations and unimpeded animal behavior. To meet this challenge, we developed ONIX, an open-source data acquisition system with high data throughput (2GB/sec) and low closed-loop latencies (<1ms) that uses a novel 0.3 mm thin tether to minimize behavioral impact. Head position and rotation are tracked in 3D and used to drive active commutation without torque measurements. ONIX can acquire from combinations of passive electrodes, Neuropixels probes, head-mounted microscopes, cameras, 3D-trackers, and other data sources. We used ONIX to perform uninterrupted, long (~7 hours) neural recordings in mice as they traversed complex 3-dimensional terrain. ONIX allowed exploration with similar mobility as non-implanted animals, in contrast to conventional tethered systems which restricted movement. By combining long recordings with full mobility, our technology will enable new progress on questions that require high-quality neural recordings during ethologically grounded behaviors.
Collapse
Affiliation(s)
- Jonathan P Newman
- Department of Brain and Cognitive Sciences, MIT, Cambridge, MA, USA
- Picower Institute for Learning and Memory, MIT, Cambridge, MA, USA
- Open Ephys Inc. Atlanta, GA, USA
| | - Jie Zhang
- Department of Brain and Cognitive Sciences, MIT, Cambridge, MA, USA
- Picower Institute for Learning and Memory, MIT, Cambridge, MA, USA
| | - Aarón Cuevas-López
- Open Ephys Inc. Atlanta, GA, USA
- Dept. of Electrical Engineering, Polytechnic University of Valencia, Valencia, Spain
- Open Ephys Production Site, Lisbon, Portugal
| | - Nicholas J Miller
- Department of Brain and Cognitive Sciences, MIT, Cambridge, MA, USA
- McGovern Institute for Brain Research, MIT, Cambridge, MA, USA
| | - Takato Honda
- Department of Brain and Cognitive Sciences, MIT, Cambridge, MA, USA
- Picower Institute for Learning and Memory, MIT, Cambridge, MA, USA
| | - Marie-Sophie H van der Goes
- Department of Brain and Cognitive Sciences, MIT, Cambridge, MA, USA
- McGovern Institute for Brain Research, MIT, Cambridge, MA, USA
| | | | | | | | - Anna Lakunina
- Allen Institute for Neural Dynamics, Seattle, Washington, USA
| | - Joshua H Siegle
- Allen Institute for Neural Dynamics, Seattle, Washington, USA
| | - Mark T Harnett
- Department of Brain and Cognitive Sciences, MIT, Cambridge, MA, USA
- McGovern Institute for Brain Research, MIT, Cambridge, MA, USA
| | - Matthew A Wilson
- Department of Brain and Cognitive Sciences, MIT, Cambridge, MA, USA
- Picower Institute for Learning and Memory, MIT, Cambridge, MA, USA
| | - Jakob Voigts
- Department of Brain and Cognitive Sciences, MIT, Cambridge, MA, USA
- Open Ephys Inc. Atlanta, GA, USA
- McGovern Institute for Brain Research, MIT, Cambridge, MA, USA
- HHMI Janelia Research Campus, Ashburn, VA, USA
| |
Collapse
|
2
|
Neto JP, Mota A, Lopes G, Coelho BJ, Frazão J, Moura AT, Oliveira B, Sieira B, Fernandes J, Fortunato E, Martins R, Igreja R, Baptista PV, Águas H. Open-source tool for real-time and automated analysis of droplet-based microfluidic. Lab Chip 2023. [PMID: 37341773 DOI: 10.1039/d3lc00327b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/22/2023]
Abstract
Droplet-based microfluidic technology is a powerful tool for generating large numbers of monodispersed nanoliter-sized droplets for ultra-high throughput screening of molecules or single cells. Yet further progress in the development of methods for the real-time detection and measurement of passing droplets is needed for achieving fully automated systems and ultimately scalability. Existing droplet monitoring technologies are either difficult to implement by non-experts or require complex experimentation setups. Moreover, commercially available monitoring equipment is expensive and therefore limited to a few laboratories worldwide. In this work, we validated for the first time an easy-to-use, open-source Bonsai visual programming language to accurately measure in real-time droplets generated in a microfluidic device. With this method, droplets are found and characterized from bright-field images with high processing speed. We used off-the-shelf components to achieve an optical system that allows sensitive image-based, label-free, and cost-effective monitoring. As a test of its use we present the results, in terms of droplet radius, circulation speed and production frequency, of our method and compared its performance with that of the widely-used ImageJ software. Moreover, we show that similar results are obtained regardless of the degree of expertise. Finally, our goal is to provide a robust, simple to integrate, and user-friendly tool for monitoring droplets, capable of helping researchers to get started in the laboratory immediately, even without programming experience, enabling analysis and reporting of droplet data in real-time and closed-loop experiments.
Collapse
Affiliation(s)
- Joana P Neto
- CENIMAT|i3N, Department of Materials Science, NOVA School of Science and Technology, NOVA University of Lisbon and CEMOP/UNINOVA, Campus de Caparica, Caparica, Portugal.
| | - Ana Mota
- CENIMAT|i3N, Department of Materials Science, NOVA School of Science and Technology, NOVA University of Lisbon and CEMOP/UNINOVA, Campus de Caparica, Caparica, Portugal.
| | | | - Beatriz J Coelho
- CENIMAT|i3N, Department of Materials Science, NOVA School of Science and Technology, NOVA University of Lisbon and CEMOP/UNINOVA, Campus de Caparica, Caparica, Portugal.
- UCIBIO, I4HB, Department of Life Sciences, NOVA School of Science and Technology, NOVA University of Lisbon, Campus de Caparica, Caparica, Portugal
| | - João Frazão
- Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisbon, Portugal
| | - André T Moura
- CENIMAT|i3N, Department of Materials Science, NOVA School of Science and Technology, NOVA University of Lisbon and CEMOP/UNINOVA, Campus de Caparica, Caparica, Portugal.
| | - Beatriz Oliveira
- UCIBIO, I4HB, Department of Life Sciences, NOVA School of Science and Technology, NOVA University of Lisbon, Campus de Caparica, Caparica, Portugal
| | - Bárbara Sieira
- CENIMAT|i3N, Department of Materials Science, NOVA School of Science and Technology, NOVA University of Lisbon and CEMOP/UNINOVA, Campus de Caparica, Caparica, Portugal.
| | - José Fernandes
- CENIMAT|i3N, Department of Materials Science, NOVA School of Science and Technology, NOVA University of Lisbon and CEMOP/UNINOVA, Campus de Caparica, Caparica, Portugal.
| | - Elvira Fortunato
- CENIMAT|i3N, Department of Materials Science, NOVA School of Science and Technology, NOVA University of Lisbon and CEMOP/UNINOVA, Campus de Caparica, Caparica, Portugal.
| | - Rodrigo Martins
- CENIMAT|i3N, Department of Materials Science, NOVA School of Science and Technology, NOVA University of Lisbon and CEMOP/UNINOVA, Campus de Caparica, Caparica, Portugal.
| | - Rui Igreja
- CENIMAT|i3N, Department of Materials Science, NOVA School of Science and Technology, NOVA University of Lisbon and CEMOP/UNINOVA, Campus de Caparica, Caparica, Portugal.
| | - Pedro V Baptista
- UCIBIO, I4HB, Department of Life Sciences, NOVA School of Science and Technology, NOVA University of Lisbon, Campus de Caparica, Caparica, Portugal
| | - Hugo Águas
- CENIMAT|i3N, Department of Materials Science, NOVA School of Science and Technology, NOVA University of Lisbon and CEMOP/UNINOVA, Campus de Caparica, Caparica, Portugal.
| |
Collapse
|
3
|
Schettino DM, Perez A, Lantigua E, Beemer O, Remmenga M, Vanicek C, Lopes G, Arzt J, Reyes R. Enhanced passive surveillance for early detection of African and classical swine fevers. REV SCI TECH OIE 2023; 42:149-160. [PMID: 37232309 DOI: 10.20506/rst.42.3358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
African swine fever (ASF) and classical swine fever (CSF) are transboundary animal diseases (TADs) of pigs. Much effort and resources are regularly put into preventing these diseases' introduction in free areas. Passive surveillance activities bring the highest chances for the early detection of TAD incursions because they are routinely and widely conducted at farms, and because these activities focus on the time between introduction and when the first sample is sent for diagnostic testing. The authors proposed the implementation of an enhanced passive surveillance (EPS) protocol based on collecting data through participatory surveillance actions using an objective and adaptable scoring system to aid the early detection of ASF or CSF at the farm level. The protocol was applied in two commercial pig farms for ten weeks in the Dominican Republic, which is a CSF- and ASF-infected country. This study was a proof of concept, based on the EPS protocol to aid detection of substantial variations in the risk score triggering testing. One of the followed farms had score variation, which triggered testing of the animals, although the test results were negative. The study enables assessment of some of the weaknesses associated with passive surveillance and provides lessons applicable to the problem. Results demonstrate the potential for overcoming some issues preventing the broad application of EPS protocols and suggest that standardised approaches may contribute to the early detection of CSF and ASF introductions.
Collapse
|
4
|
Dawar R, Carney J, Jotte R, Orsini J, Scilla K, Lopes G, Tan MH, Goh B, Tan Y, Chin T, Toh C, Samol J. PP01.74 Clinical Validation of a Promising New Amplicon-Based Liquid Biopsy Platform for Detection of Guideline Recommended Biomarkers in Metastatic NSCLC. J Thorac Oncol 2023. [DOI: 10.1016/j.jtho.2022.09.100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
5
|
Lopes G, Nogueira J, Dimitriadis G, Menendez JA, Paton JJ, Kampff AR. A robust role for motor cortex. Front Neurosci 2023; 17:971980. [PMID: 36845435 PMCID: PMC9950416 DOI: 10.3389/fnins.2023.971980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2022] [Accepted: 01/11/2023] [Indexed: 02/12/2023] Open
Abstract
The role of motor cortex in non-primate mammals remains unclear. More than a century of stimulation, anatomical and electrophysiological studies has implicated neural activity in this region with all kinds of movement. However, following the removal of motor cortex, rats retain most of their adaptive behaviors, including previously learned skilled movements. Here we revisit these two conflicting views of motor cortex and present a new behavior assay, challenging animals to respond to unexpected situations while navigating a dynamic obstacle course. Surprisingly, rats with motor cortical lesions show clear impairments facing an unexpected collapse of the obstacles, while showing no impairment with repeated trials in many motor and cognitive metrics of performance. We propose a new role for motor cortex: extending the robustness of sub-cortical movement systems, specifically to unexpected situations demanding rapid motor responses adapted to environmental context. The implications of this idea for current and future research are discussed.
Collapse
Affiliation(s)
- Gonçalo Lopes
- Champalimaud Neuroscience Programme, Champalimaud Centre for the Unknown, Lisbon, Portugal
- Sainsbury Wellcome Centre for Neural Circuits and Behaviour, University College London, London, United Kingdom
- NeuroGEARS Ltd., London, United Kingdom
| | - Joana Nogueira
- Champalimaud Neuroscience Programme, Champalimaud Centre for the Unknown, Lisbon, Portugal
- Sainsbury Wellcome Centre for Neural Circuits and Behaviour, University College London, London, United Kingdom
- NeuroGEARS Ltd., London, United Kingdom
| | - George Dimitriadis
- Champalimaud Neuroscience Programme, Champalimaud Centre for the Unknown, Lisbon, Portugal
- Sainsbury Wellcome Centre for Neural Circuits and Behaviour, University College London, London, United Kingdom
| | - Jorge Aurelio Menendez
- Sainsbury Wellcome Centre for Neural Circuits and Behaviour, University College London, London, United Kingdom
- Gatsby Computational Neuroscience Unit, University College London, London, United Kingdom
- Centre for Computation, Mathematics and Physics in the Life Sciences and Experimental Biology, University College London, London, United Kingdom
| | - Joseph J. Paton
- Champalimaud Neuroscience Programme, Champalimaud Centre for the Unknown, Lisbon, Portugal
| | - Adam R. Kampff
- Champalimaud Neuroscience Programme, Champalimaud Centre for the Unknown, Lisbon, Portugal
- Sainsbury Wellcome Centre for Neural Circuits and Behaviour, University College London, London, United Kingdom
- Voight-Kampff Ltd., London, United Kingdom
| |
Collapse
|
6
|
Mok TSK, Lopes G, Cho BC, Kowalski DM, Kasahara K, Wu YL, de Castro G, Turna HZ, Cristescu R, Aurora-Garg D, Loboda A, Lunceford J, Kobie J, Ayers M, Pietanza MC, Piperdi B, Herbst RS. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. Ann Oncol 2023; 34:377-388. [PMID: 36709038 DOI: 10.1016/j.annonc.2023.01.011] [Citation(s) in RCA: 11] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2022] [Revised: 01/16/2023] [Accepted: 01/18/2023] [Indexed: 01/27/2023] Open
Abstract
BACKGROUND We evaluated whether tissue tumor mutational burden (tTMB) and STK11, KEAP1, and KRAS mutations have clinical utility as biomarkers for pembrolizumab monotherapy versus platinum-based chemotherapy in patients with programmed death ligand- 1 (PD-L1)-positive (tumor proportion score ≥1%) advanced/metastatic non-small-cell lung cancer (NSCLC) without EGFR/ALK alterations in the phase III KEYNOTE-042 trial. PATIENTS AND METHODS This retrospective exploratory analysis assessed prevalence of tTMB and STK11, KEAP1, and KRAS mutations determined by whole-exome sequencing of tumor tissue and matched normal DNA and their associations with outcomes in KEYNOTE-042. Clinical utility of tTMB was assessed using a prespecified cut point of 175 mutations/exome. RESULTS Of 793 patients, 345 (43.5%) had tTMB ≥175 mutations/exome and 448 patients (56.5%) had tTMB <175 mutations/exome. No association was observed between PD-L1 expression and tTMB. Continuous tTMB score was associated with improved overall survival (OS) and progression-free survival among patients receiving pembrolizumab (Wald test, one-sided P < 0.001) but not those receiving chemotherapy (Wald test, two-sided P > 0.05). tTMB ≥175 mutations/exome was associated with improved outcomes for pembrolizumab versus chemotherapy, whereas tTMB <175 mutations/exome was not {OS: hazard ratio, 0.62 [95% confidence interval (CI) 0.48-0.80] and 1.09 (95% CI 0.88-1.36); progression-free survival: 0.75 (0.59-0.95) and 1.27 (1.04-1.55), respectively}. Improved OS [hazard ratio (95% CI)] for pembrolizumab versus chemotherapy was observed regardless of STK11 [STK11 mutant (n = 33): 0.37 (0.16-0.86), STK11 wild-type (n = 396): 0.83 (0.65-1.05)]; KEAP1 [KEAP1 mutant (n = 64): 0.75 (0.42-1.35), KEAP1 wild-type (n = 365): 0.78 (0.61-0.99)], or KRAS [KRAS mutant (n = 69): 0.42 (0.22-0.81); KRAS wild-type (n = 232): 0.86 (0.63-1.18)] mutation status. CONCLUSION tTMB with a cut point of ≥175 mutations/exome is a potential predictive biomarker for pembrolizumab monotherapy for advanced/metastatic PD-L1 tumor proportion score ≥1% NSCLC. Pembrolizumab is a standard first-line treatment in this setting regardless of STK11, KEAP1, or KRAS mutation status.
Collapse
Affiliation(s)
- T S K Mok
- State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
| | - G Lopes
- Sylvester Comprehensive Cancer Center at the University of Miami, Miami, FL, USA
| | - B C Cho
- Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - D M Kowalski
- Maria Sklodowska-Curie National Research Institute of Oncology, Department of Lung Cancer and Thoracic Tumours, Warsaw, Poland
| | - K Kasahara
- Kanazawa University Hospital, Kanazawa, Japan
| | - Y-L Wu
- Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
| | - G de Castro
- Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, Brazil
| | - H Z Turna
- Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey
| | | | | | - A Loboda
- Merck & Co., Inc., Rahway, NJ, USA
| | | | - J Kobie
- Merck & Co., Inc., Rahway, NJ, USA
| | - M Ayers
- Merck & Co., Inc., Rahway, NJ, USA
| | | | | | - R S Herbst
- Yale University School of Medicine, Yale Cancer Center, New Haven, CT, USA
| |
Collapse
|
7
|
Rodriguez-Abreu D, Wu YL, Boyer M, Garassino M, Mok T, Cheng Y, Hui R, Kowalski D, Robinson A, Brahmer J, Leal T, Lopes G, Cho B, Nogami N, Novello S, Peled N, de Castro G, Leiby M, Chirovsky D, Lin J, Pietanza M, Reck M. OA15.06 Pooled Analysis of Outcomes with Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
8
|
Gadgeel S, Gainor J, Cappuzzo F, Garralda E, Lee D, Mazieres J, Kim DW, Zhu V, Lopes G, Miller S, Nowicka M, Trinh H, Arndorfer S, Rahman A, Noe J, Zhang Q, Subbiah V. 984P Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
9
|
Rodriguez E, Olazagasti C, Khan K, Kareff S, Torres T, Torrents S, Fernandez-Vega Martinez G, MacIntyre J, Lopes G. EP04.01-010 Addressing Barriers to Lung Cancer Care for Diverse Populations through Patient Navigation: The University of Miami Experience. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
10
|
Gorria T, Torres-Jiménez J, Auclin E, Castro N, Albarrán-Artahona V, Ruffinelli J, Pinato D, Routy B, Nana FA, Reyes R, Viñolas N, Teixidó C, Blanc-Durand F, Planchard D, Lopes G, Nadal E, Arasanz H, Pascal M, Prat A, Reguart N, Besse B, Mezquita L. EP08.01-091 Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
11
|
Seeber A, Baca Y, Xiu J, Puri S, Owonikoko T, Oliver T, Kerrigan K, Patel S, Uprety D, Mamdani H, Kulkarni A, Lopes G, Halmos B, Borghaei H, Akerley W, Liu S, Korn W, Pircher A, Wolf D, Kocher F. 1723P CLEC3B mRNA expression levels are linked to distinct genetic backgrounds, transcriptomic signatures and survival in NSCLC. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
12
|
Drilon A, Ou SH, Gadgeel S, Johnson M, Spira A, Lopes G, Besse B, Felip E, van der Wekken A, Calles A, de Miguel M, Camidge D, Elamin Y, Liu S, Bauman J, Haggstrom D, Riley G, Pelish H, Zhu V, Lin J. EP08.02-041 NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Ocejo Gallegos J, Rodriguez E, Trabolsi A, Kareff S, Yin J, Walker P, El-Deiry W, Carneiro B, Nabhan C, Lopes G, Merchan J. 1771P Genomic characteristics and clinical outcomes of HRAS-mutated urothelial bladder cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
14
|
Torres Jiménez J, Gorria T, Auclin E, Castro N, Albarrán-Artahona V, Ruffinelli J, Pinato D, Routy B, Aboubakar Nana F, Reyes R, Viñolas N, Blanc-Durand F, Lopes G, Nadal E, Arasanz H, Pascal M, Teixidó C, Besse B, Reguart N, Mezquita L, Torres Jiménez J. EP08.01-090 Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
15
|
Lopes G, Gama VPSD, Santos IC, Branco Lopes E, Brotas G, Pereira LCJ, Cerdeira AC, Paixão JA, Rabaça S, Almeida M. Bilayer conducting salts with polymeric anions. CrystEngComm 2022. [DOI: 10.1039/d2ce00515h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Five new salts of 5-cyanobenzene-ethylenedithio-tetrathiafulvalene (CNB-EDT-TTF), with general formula (CNB-EDT-TTF)4A, and anions A= Ag(CN)2 (1), Ag(CN)2•H2O (2), Ag2(CN)3 (3), Ag(SCN)2 (4) and Hg2(SCN)5 (5), were prepared by electrocrystallisation and characterised...
Collapse
|
16
|
Rabaça S, Santos IC, Lopes G, da Gama V, Veiros LF, Almeida M. C–H⋯NC hydrogen bonding in cyanobenzene-ethylenedithio-tetrathiafulvalene compounds. CrystEngComm 2022. [DOI: 10.1039/d1ce01551f] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
The importance of C–H⋯NC interactions, which although generally considered weak, are effective in the self-assembly of crystal structures.
Collapse
Affiliation(s)
- Sandra Rabaça
- C2TN and DECN, IST, Universidade de Lisboa, E.N. 10, 2695-066 Bobadela LRS, Portugal
| | - Isabel C. Santos
- C2TN and DECN, IST, Universidade de Lisboa, E.N. 10, 2695-066 Bobadela LRS, Portugal
| | - Gonçalo Lopes
- C2TN and DECN, IST, Universidade de Lisboa, E.N. 10, 2695-066 Bobadela LRS, Portugal
| | - Vasco da Gama
- C2TN and DECN, IST, Universidade de Lisboa, E.N. 10, 2695-066 Bobadela LRS, Portugal
| | - Luís F. Veiros
- Centro de Química Estrutural, Institute of Molecular Sciences, Departamento de Engenharia Química, Universidade de Lisboa, Av. Rovisco Pais, 1049-001, Lisboa, Portugal
| | - Manuel Almeida
- C2TN and DECN, IST, Universidade de Lisboa, E.N. 10, 2695-066 Bobadela LRS, Portugal
| |
Collapse
|
17
|
Floriani F, Brandfon B, Sawczuk NJ, Lopes G, Rocha M, Oliveira D. Color difference between the vita classical shade guide and composite veneers using the dual-layer technique. J Clin Exp Dent 2022; 14:e615-e620. [PMID: 36046166 PMCID: PMC9422970 DOI: 10.4317/jced.59759] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Accepted: 06/06/2022] [Indexed: 11/28/2022] Open
Abstract
Background The purpose of this in vitro study was to evaluate the color difference between the Vita Classical Shade Guide and composite veneers using the dual-layer technique.
Material and Methods Thirty samples were fabricated using a custom-made mold (Easy Layering Shade Guide Kit, 3M) using two resin composites: Filtek Supreme Ultra (3M); and Estelite Omega (Tokuyama) (n=3). The composite veneers were made by layering the different enamel and body or dentin shades from each composite. The color measurements were taken using a spectrophotometer (Vita Easyshade V®, Vita Zahnfabrik). The ΔE00 between the Vita Classical Shade Guide (Vita Zahnfabrik) and the composite veneers were calculated using the CIEDE2000 formula.
Results For the composite veneers using Filtek Supreme Ultra, the best match for A1 Vita shade was achieved layering either EA1 with DA2 or DA3; EA2 with DA1 or DA2 (ΔE00= 1.53 ~ 1.96 ± 0.4). For A2 Vita shade the best match would be EA3 with DA3 or EA3 with DA2 (ΔE00= 1.40 ~ 1.85 ± 0.1); or for A3 Vita shade the best match would be EA3 with DA2 2.50±(0.6). For the composite veneers using Estelite Omega, the were no best match for neither A1, A2 or A3 Vita shade (ΔE00> 2.5).
Conclusions The combination of enamel and dentin shades from Filtek Supreme Ultra provided acceptable color match for A1, A2 and A3 shades from the Vita Shade Guide, while Estelite Omega did not provide acceptable color match for any of the Vita Shade Guide standard shades tested. Key words:Color, color matching, optical properties, resin composite, layering.
Collapse
|
18
|
Montoya C, Spieler B, Welford S, Dal Pra A, Diwanji T, Yechieli R, Lopes G, Mihaylov I. Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer — From Bench to Bedside. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
19
|
Rodriguez E, Alnajar A, Gawri K, Lopes G, Nguyen D, Villamizar N. OA13.02 Socioeconomic Disparities in Access to Treatment and Survival in Operable Malignant Pleural Mesothelioma in the United States. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
20
|
Chebel RC, Lopes G, Mendonça LGD, Hayes S. Effect of Gammulin supplementation during the first 24 d of life on health, growth, and first-lactation performance of Holstein cows. J Dairy Sci 2021; 104:12567-12579. [PMID: 34531050 DOI: 10.3168/jds.2020-19937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2020] [Accepted: 07/08/2021] [Indexed: 11/19/2022]
Abstract
Development and health during calfhood are paramount for the success of dairy operations because they are associated with longevity and productivity later in life. Thus, provision of nutritional supplements has been explored as an alternative to improve growth of preweaned calves. Holstein calves (female = 472, male = 46) from 2 dairies located in the San Joaquin Valley were assigned randomly to receive 25 g/d of Gammulin (APC Inc.) from 2 to 24 d of age (GAM = 263) or to receive no supplementation (control = 255). Calves were fed a mixture of waste milk and milk replacer (3.79 L/d), and study personnel added the supplement to the bottles of calves in the GAM treatment daily. Study personnel monitored calves 6 d/wk and recorded starter intake, fecal score (1 = firm, 4 = watery), and attitude score (1 = alert and responsive, 4 = recumbent). Blood samples were collected (4, 7, 14, 26, 44, 56, and 68 d of age) to determine concentrations of total protein, glucose (n = 64), nonesterified fatty acids (n = 64), β-hydroxybutyrate (n = 171), and hematocrit (n = 518). Calves (n = 64) were treated with 0.5 mg of ovalbumin at 3, 21, and 42 d of age, and concentration of anti-ovalbumin IgG was measured. The percentage of polymorphonuclear leukocytes positive for phagocytosis and oxidative burst after the ex vivo exposure to an enteropathogenic Escherichia coli was evaluated (n = 64). We followed the female calves through the end of the first lactation or until they left the herd to evaluate the effect of treatment on first-lactation performance. Treatment did not affect metabolic and immune responses. During the supplementation (1 to 24 d of age), starter intake did not differ between treatments, but the GAM treatment reduced starter intake (638.5 ± 1.1 vs. 696.6 ± 1.1 g/d; mean ± standard error of the mean) from 25 to 60 d of age and average daily gain (798.8 ± 15.4 and 749.5 ± 15.2) from 23 to 60 d of age, resulting in reduced body weight at 60 d of age (68.4 ± 0.4 vs. 69.8 ± 0.5 kg). From 1 to 24 d of age, GAM treatment reduced the number of days calves had fecal score = 4 (ratio of number of days = 0.92; 95% confidence interval = 0.84-1.00) and it reduced the number of electrolyte treatments calves received (ratio of number of treatments = 0.92; 95% confidence interval = 0.85-0.99). Treatment did not affect the hazard of first calving and first-lactation 305-d milk yield, but the adjusted hazard ratio (0.82; 95% confidence interval = 0.65, 1.04) of pregnancy in the first lactation tended to be reduced for the GAM treatment. In the conditions of this experiment, supplementation with 25 g/d of GAM to the liquid feed from 2 to 24 d of age did not improve calfhood health and performance.
Collapse
Affiliation(s)
- R C Chebel
- Veterinary Medicine Cooperative Extension, University of California-Davis, Tulare 93274; Department of Large Animal Clinical Sciences, University of Florida, Gainesville 32608; Department of Animal Sciences, University of Florida, Gainesville 32608.
| | - G Lopes
- Veterinary Medicine Cooperative Extension, University of California-Davis, Tulare 93274
| | - L G D Mendonça
- Veterinary Medicine Cooperative Extension, University of California-Davis, Tulare 93274
| | | |
Collapse
|
21
|
Lopes G, Farrell K, Horrocks EAB, Lee CY, Morimoto MM, Muzzu T, Papanikolaou A, Rodrigues FR, Wheatcroft T, Zucca S, Solomon SG, Saleem AB. Creating and controlling visual environments using BonVision. eLife 2021; 10:e65541. [PMID: 33880991 PMCID: PMC8104957 DOI: 10.7554/elife.65541] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2020] [Accepted: 04/20/2021] [Indexed: 01/10/2023] Open
Abstract
Real-time rendering of closed-loop visual environments is important for next-generation understanding of brain function and behaviour, but is often prohibitively difficult for non-experts to implement and is limited to few laboratories worldwide. We developed BonVision as an easy-to-use open-source software for the display of virtual or augmented reality, as well as standard visual stimuli. BonVision has been tested on humans and mice, and is capable of supporting new experimental designs in other animal models of vision. As the architecture is based on the open-source Bonsai graphical programming language, BonVision benefits from native integration with experimental hardware. BonVision therefore enables easy implementation of closed-loop experiments, including real-time interaction with deep neural networks, and communication with behavioural and physiological measurement and manipulation devices.
Collapse
Affiliation(s)
| | - Karolina Farrell
- UCL Institute of Behavioural Neuroscience, Department of Experimental Psychology, University College LondonLondonUnited Kingdom
| | - Edward AB Horrocks
- UCL Institute of Behavioural Neuroscience, Department of Experimental Psychology, University College LondonLondonUnited Kingdom
| | - Chi-Yu Lee
- UCL Institute of Behavioural Neuroscience, Department of Experimental Psychology, University College LondonLondonUnited Kingdom
| | - Mai M Morimoto
- UCL Institute of Behavioural Neuroscience, Department of Experimental Psychology, University College LondonLondonUnited Kingdom
| | - Tomaso Muzzu
- UCL Institute of Behavioural Neuroscience, Department of Experimental Psychology, University College LondonLondonUnited Kingdom
| | - Amalia Papanikolaou
- UCL Institute of Behavioural Neuroscience, Department of Experimental Psychology, University College LondonLondonUnited Kingdom
| | - Fabio R Rodrigues
- UCL Institute of Behavioural Neuroscience, Department of Experimental Psychology, University College LondonLondonUnited Kingdom
| | - Thomas Wheatcroft
- UCL Institute of Behavioural Neuroscience, Department of Experimental Psychology, University College LondonLondonUnited Kingdom
| | - Stefano Zucca
- UCL Institute of Behavioural Neuroscience, Department of Experimental Psychology, University College LondonLondonUnited Kingdom
| | - Samuel G Solomon
- UCL Institute of Behavioural Neuroscience, Department of Experimental Psychology, University College LondonLondonUnited Kingdom
| | - Aman B Saleem
- UCL Institute of Behavioural Neuroscience, Department of Experimental Psychology, University College LondonLondonUnited Kingdom
| |
Collapse
|
22
|
Lopes G, Monteiro P. New Open-Source Tools: Using Bonsai for Behavioral Tracking and Closed-Loop Experiments. Front Behav Neurosci 2021; 15:647640. [PMID: 33867952 PMCID: PMC8044343 DOI: 10.3389/fnbeh.2021.647640] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2020] [Accepted: 03/08/2021] [Indexed: 11/28/2022] Open
Abstract
The ability to dynamically control a behavioral task based on real-time animal behavior is an important feature for experimental neuroscientists. However, designing automated boxes for behavioral studies requires a coordinated combination of mechanical, electronic, and software design skills which can challenge even the best engineers, and for that reason used to be out of reach for the majority of experimental neurobiology and behavioral pharmacology researchers. Due to parallel advances in open-source hardware and software developed for neuroscience researchers, by neuroscience researchers, the landscape has now changed significantly. Here, we discuss powerful approaches to the study of behavior using examples and tutorials in the Bonsai visual programming language, towards designing simple neuroscience experiments that can help researchers immediately get started. This language makes it easy for researchers, even without programming experience, to combine the operation of several open-source devices in parallel and design their own integrated custom solutions, enabling unique and flexible approaches to the study of behavior, including video tracking of behavior and closed-loop electrophysiology.
Collapse
Affiliation(s)
| | - Patricia Monteiro
- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal
- ICVS/3B’s–PT Government Associate Laboratory, Braga/Guimaraes, Portugal
| |
Collapse
|
23
|
Rodriguez E, Khan K, Torres T, Dawar R, Gawri K, Ikpeazu C, Lopes G. P36.01 KEAP1 and NRF2 Mutations in Hispanic and Non-Hispanic Patients with NSCLC: Clinicopathologic Characteristics and Prognosis. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
24
|
Dawar R, Gawri K, Rodriguez E, Thammineni V, Saul E, Lima Filho JO, Dempsey N, Khan K, Torres T, Kwon D, Lopes G. P01.09 Improved Outcomes With Ramucirumab & Docetaxel in Metastatic Non-Small Cell Lung Cancer After Failure of Immunotherapy. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.333] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
25
|
Cho B, Wu Y, Lopes G, Kudaba I, Kowalski D, Turna H, De Castro G, Caglevic C, Zhang L, Karaszewska B, Laktionov K, Srimuninnimit V, Bondarenko I, Kubota K, Yin L, Lin J, Souza F, Mok T. FP13.04 KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.143] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
26
|
Basher F, Saravia D, Lopes G. P37.12 Concordance of Next-Generation Sequencing Between Tissue and Liquid Biopsies in Non-Small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
27
|
Riudavets M, Mezquita L, Auclin E, Benitez J, Le Pechoux C, Majem M, Dempsey N, Lobefaro R, Nadal E, Amores A, Menis J, Tagliamento M, López-Castro R, Ponce S, Bosch-Barrera J, Aboubakar F, Mosquera J, Pilotto S, Reyes R, Mielgo X, Duchemann B, Mosteiro M, Mussat E, De Giglio A, Scheffler M, Campayo M, Botticella A, Naltet C, Lavaud P, Lopes G, Signorelli D, Garcia-Campelo R, Besse B, Planchard D. MA08.04 LIPI and outcomes of durvalumab as consolidation therapy after ChRT in patients with locally-advanced NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
28
|
Bravo Montenegro G, Vanderwalde A, Raez L, Nieva J, Feldman R, Herrmann A, Nagasaka M, Ikpeazu C, Mamdani H, Pai S, Wozniak A, Spira A, Lopes G, Liu S, Kim C. P76.43 Co-occurring genomic alterations and treatment outcomes in patients with EGFR exon 20 insertion positive NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1100] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Kane GA, Lopes G, Saunders JL, Mathis A, Mathis MW. Real-time, low-latency closed-loop feedback using markerless posture tracking. eLife 2020; 9:e61909. [PMID: 33289631 PMCID: PMC7781595 DOI: 10.7554/elife.61909] [Citation(s) in RCA: 50] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2020] [Accepted: 12/06/2020] [Indexed: 02/06/2023] Open
Abstract
The ability to control a behavioral task or stimulate neural activity based on animal behavior in real-time is an important tool for experimental neuroscientists. Ideally, such tools are noninvasive, low-latency, and provide interfaces to trigger external hardware based on posture. Recent advances in pose estimation with deep learning allows researchers to train deep neural networks to accurately quantify a wide variety of animal behaviors. Here, we provide a new DeepLabCut-Live! package that achieves low-latency real-time pose estimation (within 15 ms, >100 FPS), with an additional forward-prediction module that achieves zero-latency feedback, and a dynamic-cropping mode that allows for higher inference speeds. We also provide three options for using this tool with ease: (1) a stand-alone GUI (called DLC-Live! GUI), and integration into (2) Bonsai, and (3) AutoPilot. Lastly, we benchmarked performance on a wide range of systems so that experimentalists can easily decide what hardware is required for their needs.
Collapse
Affiliation(s)
- Gary A Kane
- The Rowland Institute at Harvard, Harvard UniversityCambridgeUnited States
| | | | - Jonny L Saunders
- Institute of Neuroscience, Department of Psychology, University of OregonEugeneUnited States
| | - Alexander Mathis
- The Rowland Institute at Harvard, Harvard UniversityCambridgeUnited States
- Center for Neuroprosthetics, Center for Intelligent Systems, & Brain Mind Institute, School of Life Sciences, Swiss Federal Institute of Technology (EPFL)LausanneSwitzerland
| | - Mackenzie W Mathis
- The Rowland Institute at Harvard, Harvard UniversityCambridgeUnited States
- Center for Neuroprosthetics, Center for Intelligent Systems, & Brain Mind Institute, School of Life Sciences, Swiss Federal Institute of Technology (EPFL)LausanneSwitzerland
| |
Collapse
|
30
|
Mihaylov I, Lopes G, Saravia D, Kwon D, Yechieli R, Pra AD, Freedman L, Diwanji T, Spieler B. PO-1006: Immunotherapy related pneumonitis correlates with radiomics in NSCLC patients treated with Nivolumab. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01023-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
31
|
Spieler B, Azzam G, Kwon D, Saravia D, Lopes G, Dal Pra A, Diwanji T, Yechieli R, Freedman L, Mihaylov I. Checkpoint Inhibitor Pneumonitis in Patients with Advanced NSCLC on Nivolumab Monotherapy is Underreported and Associated with Prior Radiotherapy History. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1188] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
32
|
Keam B, Hu M, Subbiah V, Wirth L, Schuler M, Mansfield A, Brose M, Curigliano G, Leboulleux S, Zhu V, Matos I, Adkins D, Baik C, Lopes G, Godbert Y, Sarker D, Zhang H, Turner C, Taylor M, Lin CC. 442P Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.434] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
33
|
Cruz B, Lenz G, Pellegrini R, Lago L, Azevedo P, Tôrres L, Lopes G, Teodoro J. 1602P Estimated years of potential life lost from lack of access to crizotinib: NSCLC ALK+. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
34
|
Wise-Draper T, Desai A, Elkrief A, Rini B, Flora D, Bowles D, Shah D, Rivera D, Johnson D, Lopes G, Grivas P, Thompson M, Peters S, Kuderer N, Nock N, Grover P, Li X, Gulati S, Choueiri T, Warner J. LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis. Ann Oncol 2020. [PMCID: PMC7506308 DOI: 10.1016/j.annonc.2020.08.2312] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
35
|
Grivas P, Warner J, Shyr Y, Shah D, Rubinstein S, Kuderer N, Choueiri T, Rivera D, Painter C, Thompson M, Peters S, Desai A, Khaki A, Pennell N, Hawley J, Halmos B, Puc M, Lyman G, Rini B, Lopes G. LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19). Ann Oncol 2020. [PMCID: PMC7506465 DOI: 10.1016/j.annonc.2020.08.2313] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
36
|
Pino LE, Triana I, Pérez C, Piotrostanalzki A, Ruiz-Patiño A, Lopes G, Cardona AF. Electronic nicotine delivery systems (ECs) and COVID-19: the perfect storm for young consumers. Clin Transl Oncol 2020; 23:5-9. [PMID: 32447647 PMCID: PMC7245506 DOI: 10.1007/s12094-020-02391-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Accepted: 05/10/2020] [Indexed: 12/19/2022]
Abstract
The COVID-19 pandemic caused a change in our society and put health systems in crisis worldwide. Different risk factors and comorbidities have been found that increase the risk of mortality when acquiring this infection. The use of alternative devices to the cigarette like the electronic cigarettes, the vapers have been studied widely and generators of great controversy since it has been discovered that they also produce different pulmonary affections. When developing the SARS-CoV2 infection, different theories have been generated about the greater predisposition to a worse prognosis of people who use electronic cigarettes; however, the information on this continues in discovery. A group of experts made up of oncologists, infectologists, pulmonologists, and epidemiologists met to review the literature and then generate theories about the impact of electronic cigarettes on SARS-CoV2 infection.
Collapse
Affiliation(s)
- L. E. Pino
- Cancer Institute Fundación Santafé, 110121 Bogotá, Colombia
| | - I. Triana
- Cancer Institute Fundación Santafé, 110121 Bogotá, Colombia
| | - C. Pérez
- Infectious Disease Department Clínica, Marly - Hospital La Samaritana, 110121 Bogotá, Colombia
| | - A. Piotrostanalzki
- Respiratory Medicine Department, Clínica Central del Quindío, 110121 Armenia, Colombia
| | - A. Ruiz-Patiño
- Clinical and Traslational Oncology Group, Institute of Oncology, Country Clinic, 110121 Bogotá, Colombia
| | - G. Lopes
- Sylvester Comprehensive Cancer Center, Miami University, Miami, USA
| | - A. F. Cardona
- Clinical and Traslational Oncology Group, Institute of Oncology, Country Clinic, 110121 Bogotá, Colombia
- Foundation for Clinical and Applied Cancer Research - FICMAC, 110121 Bogotá, Colombia
- Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad El Bosque, 110121 Bogotá, Colombia
| |
Collapse
|
37
|
Seruga B, Sullivan R, Fundytus A, Hopman W, Ocana A, Joffe J, Bodoky G, Le Tourneau C, Vanderpuye V, Lopes G, Hammad N, Sengar M, Brundage M, Booth C. Medical Oncology Workload in Europe: One Continent, Several Worlds. Clin Oncol (R Coll Radiol) 2020; 32:e19-e26. [DOI: 10.1016/j.clon.2019.06.017] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2019] [Revised: 04/16/2019] [Accepted: 05/23/2019] [Indexed: 01/30/2023]
|
38
|
Herbst R, Lopes G, Kowalski D, Kasahara K, Wu YL, De Castro G, Cho B, Turna H, Cristescu R, Aurora-Garg D, Lunceford J, Kobie J, Ayers M, Pietanza M, Piperdi B, Mok T. LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz453.001] [Citation(s) in RCA: 47] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Saravia D, Basher F, Arora A, Soong D, Fanfan D, Cotta J, Lopes G. P2.06 Lung Cancer Driver Mutations and PD-L1 Expression in US Latino Patients with Advanced Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
40
|
Lee D, Subbiah V, Gainor J, Taylor M, Zhu V, Doebele R, Lopes G, Baik C, Garralda E, Gadgeel S, Kim DW, Turner C, Palmer M, Miller S, Curigliano G. Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz431] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Magalhaes M, Aguiar P, Haaland B, del Giglio A, Lopes G. Meta-analysis in HER2+ early breast cancer therapies and cost-effectiveness in a Brazilian perspective. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz240.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
42
|
Raez L, Saravia D, Sumarriva D, Ruiz R, Izquierdo P, Cress D, Hunis B, Mas L, Lopes G, Kaen D. P2.16-15 Survival and Clinical Immunotherapy Outcomes in Hispanic Patients vs Non-Hispanic White Patients with Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
43
|
San Tan P, Aguiar Junior PN, Husnain M, Haaland B, Lopes G. P1.04-67 First-Line Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer (NSCLC) – A Network Meta-Analysis by PD-L1. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
44
|
Curigliano G, Subbiah V, Gainor J, Lee D, Taylor M, Zhu V, Doebele R, Lopes G, Baik C, Garralda E, Gadgeel S, Kim DW, Turner C, Palmer M, Miller S. Treatment with BLU-667, a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and thyroid cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz268.093] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
Mezquita L, Preeshagul I, Auclin E, Saravia D, Hendriks L, Rizvi H, Planchard D, Park W, Nadal E, Ruffinelli J, Ponce S, Audigier-Valette C, Carnio S, Novello S, Zalcman G, Majem M, Mariniello A, Dingemans A, Lopes G, Rossoni C, Pignon J, Chaput N, Hellmann M, Arbour K, Besse B. MA07.02 Early Change of dNLR Is Correlated with Outcomes in Advanced NSCLC Patients Treated with Immunotherapy. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.548] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
46
|
Herbst R, Lopes G, Kowalski D, Nishio M, Wu YL, de Castro Junior G, Baas P, Kim DW, Gubens M, Cristescu R, Aurora-Garg D, Albright A, Ayers M, Loboda A, Lunceford J, Kobie J, Lubiniecki G, Pietanza M, Piperdi B, Mok T. Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.077] [Citation(s) in RCA: 45] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
47
|
Spieler B, Azzam G, Asher D, Lopes G, Saravia D, Kwon D, Yechieli R, Pra AD, Diwanji T, Mihaylov I. Overall Survival of Patients with Advanced NSCLC Treated with Nivolumab Correlates with Texture Features on Pre-Immunotherapy CT Imaging and Radiotherapy History. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.2438] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
48
|
Jesus R, Conceição C, Lopes G. Gamifying the visit to places with valuable landscapes. EAI Endorsed Transactions on Creative Technologies 2019. [DOI: 10.4108/eai.30-7-2019.162946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
49
|
Mok T, Wu YL, Kudaba I, Kowalski D, Cho B, Turna H, de Castro G, Srimuninnimit V, Laktionov K, Bondarenko I, Kubota K, Caglevic C, Karaszewska B, Dang T, Yin L, Penrod J, Lopes G. Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
50
|
Nosaki K, Hosomi Y, Saka H, Baas P, de Castro G, Reck M, Wu YL, Brahmer J, Felip E, Sawada T, Noguchi K, Han S, Piperdi B, Kush D, Lopes G. Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1–positive advanced NSCLC: Pooled analysis from KEYNOTE-010, -024, and -042. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|